Supplementary Figure 9 from ERBB2/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer

Key Points

• HER2 variance in tumor tissues is significant for understanding metastatic urothelial cancer.
• The analysis indicates variability in HER2 immunohistochemistry across different tumor samples.
• Observational analysis examines ctDNA and tissue alterations in patients with metastatic urothelial cancer.
• Understanding HER2 alterations may highlight therapeutic targets for these cancer patients.